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Abstract 
Objective 
To develop and validate a gastrointestinal (GI) symptom rating questionnaire for 
patients with luminal gastrointestinal symptoms including where no diagnosis has been 
made.   
Study Design and Setting 
We developed and validated the Gastrointestinal symptom rating questionnaire (GSRQ) 
in three stages: 1) item generation to identify the relevant items for scale inclusion; 2) 
development and piloting on patients with a known gastrointestinal disorder; and 3) 
testing in a sample of trial patients.  We examined the underlying dimensions of the 
scale, internal consistency, validity, reproducibility and responsiveness.   
Results 
We identified four interpretable factors on the GSRQ.  The GSRQ had good internal 
consistency, (corrected item-subscale correlations between 0.4 and 0.8), and Cronbach’s 
alpha greater than 0.7 for each sub-scale.   Construct validity was demonstrated by 
modest but significant correlations with the SF-36 and the EQ5D index value.  We 
demonstrated good reproducibility with intra-class correlations for test retest scores 
between 0.71 and 0.77, and significant responsiveness ratios for all sub-scales in 
patients who had improved, and in two of the sub-scales in patients who had 
deteriorated.  
Conclusion 
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The GSRQ could be a useful tool to monitor quality of life in various luminal 
gastrointestinal conditions and where a formal diagnosis has not been made.  
Key words 
quality of life, gastrointestinal symptoms, validation, development, psychometric 
analysis 
 
Running head 
The Gastrointestinal Symptom Rating Questionnaire 
 
What is new? 
Key findings 
 The GSRQ was successfully validated on patients with no confirmed diagnosis as 
well as during the course of treatment following diagnosis 
What this study adds to what is known 
 Valid health related quality of life (HRQL) instruments are needed to assess and 
monitor patients attending clinics with gastrointestinal (GI) symptoms.  Although 
numerous questionnaires exist to measure HRQL in patients with GI symptoms, 
there are no validated instruments available for use at first referral when a 
diagnosis has not been made.  The GSRQ has the potential to help monitor HRQL 
in patients before formal diagnosis and during the longitudinal course of their 
disease 
What is the implication? 
 The GSRQ has the potential to help monitor HRQL in patients before formal 
diagnosis and during the longitudinal course of their disease 
What should change now? 
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 The GSRQ should be routinely used in clinical practice to measure health related 
quality of life in a variety of luminal disorders 
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Introduction 
Monitoring patient health related quality of life (HRQL) has become a key part of 
research and health care in recent years.  Gastrointestinal (GI) symptoms are common 
in the adult and elderly population in North America, Europe and the UK[1,2,3].  In 
Europe the prevalence of upper GI symptoms ranges from 25 to 35% and for lower GI 
symptoms from 3 to 22%[4,5].  It is estimated that up to 40% of adults in the UK suffer 
from GI symptoms in any one year[6,7,8].  In addition, around 50% of new referrals to 
secondary care gastroenterology clinics are patients who present with GI symptoms but 
no identifiable structural or biochemical abnormalities[9,10].   These GI symptoms 
adversely affect patients’ well-being and their ability to enjoy day-to-day activities[11].  
Valid instruments are therefore needed to assess and monitor the progress of patients 
attending gastroenterology clinics with gastrointestinal symptoms. 
 
There has been some success in using generic instruments such as such as the Short 
Form 36 (SF36)[12], Psychological General Wellbeing Scale (PGWB)[13] and Sickness 
Impact Profile (SIP)[14],  to assess the health status of GI patients.   However, there are 
concerns that these instruments might miss small but clinically important changes[15]. 
 
Since the 1990s, there has been an exponential growth in the number of quality of life 
measures developed for patients with GI disorders [15,16].  Disease-specific instruments 
have been developed for inflammatory bowel disease (IBD), irritable bowel syndrome 
(IBS), dyspepsia, gastroesophageal reflux disease (GORD), liver disease and GI 
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malignancy[17,18].  There are however, many disorders for which no valid instruments 
exist.  Furthermore, it is not always appropriate to use disease-specific instruments for 
newly-referred patients who have not yet had a confirmed diagnosis. The EORTC Quality 
of Life Group (http://groups.eortc.be/qol/) have recently developed quality of life 
questionnaires for patients with cancer, with modular ‘add-ons’ for GI disorders, such as 
the EORTC QLC-GINET21[18].  These may have been a useful starting point for our 
instrument development, however they were not available when we undertook the 
study.   
 
Classification and management of GI disorders is often symptom based, and it is 
common for people with different GI disorders, to have similar symptoms[19].  Disease 
specific instruments for different GI disorders, even those supposed to be related to 
different anatomic regions, often ask patients’ views on similar symptom groups[15,16].   
However, it is doubtful whether disease-specific instruments that assess HRQL in one 
single GI disorder are appropriate for assessing the health status of all GI patients.   
GI luminal disorders cover disorders along the entire GI tract from the mouth to the 
bowel, and in the course of diagnosis and monitoring would require a much broader 
assessment of symptoms than the specific questions that are asked in disease-specific 
questionnaires.   To capture small but clinically important changes in GI symptoms, an 
optimum approach for patients with luminal disorders would be to use a system-specific 
instrument, i.e. one developed for all GI disorders.  There are very few of these systemic 
instruments available.  The most well-known, the Gastrointestinal Quality of Life Index 
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(GIQLI)[20] is validated for use with patients with a confirmed diagnosis. In the course of 
undertaking evaluations of interventions that were designed to make a diagnosis the 
research team became aware that there was no validated instrument available that 
could be used at first referral and be applied to patients where no confirmed diagnosis 
had been made; and that could subsequently be used longitudinally to follow the course 
of the disease on the basis of their symptoms. The aim of this study therefore was to 
develop and validate a symptom-rating questionnaire suitable to measure the health 
status of patients with luminal GI symptoms referred to secondary care and in particular 
where a diagnosis has not been established.  This publication focuses on the in-depth 
validation of this new measure- the Gastrointestinal Symptom Rating Questionnaire 
(GSRQ).   
Materials and Methods 
We adapted Streiner and Norman’s approach[21] to develop the instrument in the 
following four stages: 
Stage 1: Item generation for the Gastrointestinal Symptom Rating Scale (GSRQ) 
Stage 2: Pilot study at a local hospital for initial validation 
Stage 3: Main study for concurrent validation in the context of a national multi-
institution nurse endoscopy trial (MINuET)[22,23]. 
 
Stage 1:  Item generation 
We carried out a detailed review of the literature using the search terminology ‘quality 
of life’, ‘questionnaire’, ‘validation’ and ‘gastroenterology’, in order to determine the 
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most relevant items for a gastrointestinal symptom rating scale.  We identified a 
number of existing questionnaires which contained items that were potentially suitable 
for inclusion in the development of a new scale (UK Inflammatory Bowel Disease 
Questionnaire (UK IBDQ)[24], the Aberdeen Dyspepsia Scale (ADS)[25], the Gastro-
oesophageal Reflux Disease Health Related Quality of Life Scale (GERD-HRQLS)[26],the 
Irritable Bowel Syndrome Quality of Life Questionnaire (IBS QOL)[27], the 
Gastrointestinal Symptom Rating Questionnaire (GSRQ)[28] and the Gastrointestinal 
Quality of Life Index (GIQLI)[20]).   
 
A panel of clinicians, patients and public with expertise in gastroenterology, psychology, 
outcome measurement and methodology reviewed these items and developed the 
initial version of the GSRQ containing 30 items (see Appendix 1).  The panel were asked 
whether they considered that all appropriate symptoms had been included in the 
questionnaire, that the questions were appropriately worded and that they were 
suitable for patients with and without a diagnosis of a GI luminal disorder. 
 
In addition, we separately piloted the developed questionnaire with a purposive sample 
of 10 patients with a confirmed GI condition from a local hospital (Neath PortTalbot, 
UK).  Patients were asked to complete the questionnaire as well as four supplementary 
questions: 
 Did you find any of the questions difficult to understand? 
o Yes/No.  If yes, which one(s) and why? 
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 Was there any question you did not want to answer? 
o Yes/No.  If yes, which one(s) and why? 
 Were there any specific aspects of your bowel condition that were not covered by 
these questions? 
o Yes/No.  If yes, which one(s) and why? 
 Did you find any of these questions not applicable to you? 
o Yes/No.  If yes, which one(s) and why? 
 
The questions were organized into hypothesized domains on the basis of similarity of 
symptoms. 
 
Stage 2: Pilot study initial validation 
We carried out an initial validation of the GSRQ on a sample of patients with a known 
luminal GI disorder (Dyspepsia, GORD, IBD and IBS) at a local hospital (Neath PortTalbot, 
UK).  We invited patients to complete a questionnaire containing the 30 item GSRQ as 
well as the validated generic SF36 at home.  We also asked patients some semi-
structured questions about the format and content of the GSRQ.  We asked patients to 
complete the questionnaires at baseline and four weeks. 
 
We carried out exploratory principal components analysis on the pilot sample to 
determine the factorability of the data and the underlying dimensions of the GSRQ.  We 
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examined the Bartlett’s test of sphericity and the Kaiser- Meyer-Olkin (KMO) measure of 
sampling adequacy to determine if principal components analysis was appropriate. 
 
Stage 3: Main study 
We validated the GSRQ on a separate sample of patients.  We included patients 
recruited to the MINuET trial to validate the GSRQ.  MINuET was a 23-hospital 
randomised trial designed to compare gastrointestinal endoscopy (flexisigmoidoscopy 
and oesophagogastroduodenoscopy (OGD)) performed by doctors and nurses[22,23].  
We undertook concurrent validation of the GSRQ with new patients taking part in 
MINuET and for whom a diagnosis had not yet been confirmed.  We invited patients to 
complete a questionnaire containing the GSRQ, SF36 and EQ5D at recruitment, one 
month and 12 months.  In the one and 12 month questionnaires, we asked patients if 
their condition had remained stable, got better or worse.  We followed the practice of 
using self-reported global rating documented in existing literature to assess the 
reproducibility and responsiveness of the GSRQ[24,29,30,31,32,33].  We used patient 
data collected at recruitment and one month to test the psychometric properties of the 
GSRQ.   
 
Patient data collection for the pilot and main study was carried out between January 
and April 2002.  
 
Statistical analysis 
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We carried out the following psychometric analysis on the completed questionnaires 
from the main study: 
Assessing underlying dimensions and internal consistency 
We carried out principal components analysis (applying oblimin rotation).   We 
considered that a was factor important if its eigenvalue exceeded 1.  In addition we 
explored the face validity of the factor, that is, it appeared at “face value” to be 
measuring a clinically recognizable symptoms related to  the patient’s health.  We only 
considered those items as contributing to a subscale if they had a factor loading of at 
least 0.4 on that factor[34].   
 
We assessed the internal consistency of the GSRQ sub-scales by examining the item-
total correlations (the statistical correlation of each item with the total sub-scale score) 
and Cronbach’s alpha.  We considered items for rejection if their item-total correlations 
were below 0.4 or above 0.8.  We also examined items for floor and ceiling effects. We 
considered items for rejection if more than 80% of patients gave the same response 
because such items were not sensitive enough to discriminate different levels of 
severity.  We examined the Cronbach’s alpha for each of the resulting scales to ensure 
they exceeded 0.7[21,35]. 
 
Assessing validity 
We evaluated the construct validity of the GSRQ questionnaire by correlation with the 
patients’ general health as measured by the generic SF36 and EQ-5D questionnaires.  If 
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the GSRQ and its subscales were valid measures of the effect of GI symptoms on health, 
we would expect that they would show significant small to moderate levels of negative 
correlation with the SF-36 scales and EQ5D index value[35].  In addition, if the GSRQ 
subscales were valid measure of GI symptoms, we would expect patients referred to 
receive an OGD to score worse on those GSRQ subscales related to upper GI symptoms 
and those referred to receive flexisigmoidoscopy to score worse on those GSRQ 
subscales related to lower GI symptoms.  
 
Assessing reproducibility 
We assessed reproducibility by comparing patients’ GSRQ scores at recruitment and at 
one month.  It has been suggested that a period of 1-2 weeks is the most appropriate to 
assess test-retest reliability[21], however we chose a period of one month to coincide 
with the next clinical appointment.  We expected that for patients reporting no change 
in their gastrointestinal symptoms, their scores at recruitment and at one month should 
be consistent.  We assessed the reproducibility of the scores for stable patients using 
the  intraclass correlation[36].   
 
Assessing responsiveness 
We assessed the responsiveness of the GSRQ in those patients’ reporting either an 
improvement or a deterioriation in their gastrointestinal symptoms a month after 
recruitment.  We used Guyatt’s responsiveness statistics to quantify the responsiveness 
of GSRQ[36].  
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Details of final scoring 
In analysing and validating the final version of the GSRQ we calculated sub-scale scores 
thus: 
1. As all the questions assessed response in the same direction, therefore no 
transformation of the scales was necessary. 
2. All questions had five response options (not at all, once a week, two or three times a 
week, most days, every day).  We scored each question in ascending order of 
severity  from 0 to 4. 
3. We gave all questions equal weighting. 
4. We calculated the GSRQ sub-scale scores by summing all the responses from the 
final selected questions for that sub-scale and dividing by the number of valid 
responses.   
5. We transformed the GSRQ sub-scale scores to a 0-100 scale using the formula: 
((score-lowest possible score/score range) x100). 
6. A higher GSRQ sub-scale score indicated worse symptom severity. 
 
If individual question responses were missing, we still calculated sub-scale scores when 
at least 50% of the questions for that sub-scale had been completed.  The sub-scale 
score was calculated by summing the responses to each answered question and dividing 
by the number of completed questions.  If patients had completed fewer than 50% of 
the questions for a particular sub-scale, we treated that GSRQ sub-scale score as 
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missing.  It was possible therefore for a patient to have scores for some of the sub-
scales but not for others depending on which questions the patient had completed. 
 
Ethics  
The study was approved by the Multicentre Research Ethics Committee for Wales. We 
also obtained approval from all the United Kingdom participating sites local research 
ethics committees (Ayr Hospital; Crosshouse Hospital, Kilmarnock; Darlington Memorial 
Hospital; Gartnavel General Hospital, Glasgow; George Eliot Hospital, Nuneaton; 
Kettering General Hospital; Leicester Royal Infirmary; Royal Albert Edward Infirmary, 
Wigan; Monklands Hosital, Airdrie; City General Hospital, Stoke on Trent; Northampton 
General Hospital; Oldchurch Hospital, Romford; Queen Alexandra Hospital, Portsmouth; 
Queen’s Medical Centre, Nottingham; Rotherham General Hospital).  All patients 
provided written informed consent to participate in the study.  
 
Results 
Stage 1:  Item generation 
We developed the initial version of the GSRQ following expert review of items identified 
from literature (see Appendix 1).  Many of the questions in the initial version were 
drawn from the existing questionnaires and were assimilated and modified to ensure 
they were appropriate to patients where no confirmed diagnosis had yet been made. 
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The initial questionnaire contained six sections covering a comprehensive range of 
common GI symptoms.  Each section contained two components relating to 1) the 
presence of symptoms and 2) the impact of these symptoms on daily living.  We 
designed the questionnaire to allow patients who did not have some of the symptoms in 
the GSRQ to skip the questions related to the impact of these symptoms on their daily 
living.  The GSRQ took approximately 5 minutes to complete. 
 
Stage 2: Pilot study initial validation 
A total of 351 patients were recruited for the initial validation and completed the 
baseline questionnaire. Of these, 308 also completed the four week questionnaire.  
Analysis of preliminary findings from the initial validation showed three dimensions 
underlying GI symptoms reported by these patients. (1. Upper GI symptoms, 2. Lower GI 
symptoms – frequent bowel movement and related symptoms and 3. Lower GI – 
constipation related symptoms). Good internal consistency was recorded among the 
dimensions (Cronbach’s alpha range 0.86 to 0.91).   
 
Construct validity was demonstrated by statistically significant correlations between the 
three GSRQ dimensions with five of the eight SF36 subscales (physical functioning, role 
physical, pain, general health and role emotional). The upper GI dimension was also 
correlated with the SF36 mental health subscale.  Analysis of the semi-structured 
questions showed that patients found the questionnaire easy to complete and there 
were no questions they did not wish to answer.   
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Stage 3: Main study 
1888 patients consented to take part in MINuET, of whom 1099 were referred to 
received flexi-sigmoidoscopy and 789 referred to receive OGD.  The questionnaire was 
completed by 1782 patients at recruitment and 1427 at one month.  
Psychometric Analysis 
Underlying dimensions  
Initial exploratory principal component analysis identified a number of items that were 
candidates for removed from the scale.  We identified that items addressing the 
possible impact of very different types of GI symptoms were loaded on the same factor 
(items 3, 9, 14, 18, 27; see Appendix 1).  These were also items which patients were 
allowed to skip if they did not have some of the GI symptoms.  Their factor loadings 
could therefore be reflecting a statistical artefact rather than genuine correlation.   Two 
items (item 19- weight change and item 26- bleeding in back passage) did not contribute 
to any of the factors and were also considered to be candidates for removal.  Item 28 
(change in symptoms) similarly did not contribute to any factor and also had a 
comparatively high response rate to one category (70%).  Item 8 (blood in vomit) also 
had a high response rate to one category (91%).  We identified from the exploratory 
principal components analysis that items 29 and 30 loaded on more than one factor and 
formed one factor on their own.  Item 29 asked patients’ about their difficulty in getting 
to sleep and item 30 asked about the patient waking up at night.  On examining the 
content of the two items, we felt that they were too similar and they did not make a 
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genuine factor.  We made a decision to exclude the five optional and further six items 
from the final principal components analysis.   
 
We carried principal components analysis on the remaining 19 items and identified a 
four-factor solution. The solution was deemed to be satisfactory and factors extracted 
were used in the assessment of internal consistency, construct validity, reproducibility 
and responsiveness.  Each item was given an equal weight and was scored from 0 (not at 
all) to 4 (everyday).  As all questions were asked in the same way, we did not carry out 
any transformations.   
 
Table 1 illustrates the results of the final principal component analysis.  The number of 
patients responding to each item ranged from 1131 to 1767, except for item 8 where 
368 patients responded.   We show all factor loadings of 0.4 or above, with those in 
parentheses illustrating that the relevant item had been excluded from one factor in 
favour of another.  
 
We identified four subscales from the principal components analysis underlying the GI 
symptoms (see Appendix 2):  
1. Upper GI symptoms – heartburn (Q1), reflux (Q2), nausea (Q3), retching (Q4), 
vomiting (Q5), food sticking in gullet (Q11), eating restricted (Q12) and lack of 
appetite (Q13). 
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2. Wind-related symptoms – upper abdomen discomfort (Q6), belching (Q7), wind 
from bowel (Q8), trapped wind (Q9) and gurgling in stomach (Q10). 
3. Lower GI symptoms- frequent bowel movement (Q14), loose stools (Q15) and 
urgent need to empty bowel (Q18). 
4. Defecation-related symptoms – hard stools (Q16), constipation (Q17) and 
incomplete bowel emptying (Q19). 
 
Internal consistency  
Table 2 shows the internal consistency of the four GSRQ subscales.  None of the 
questions in the four subscales had a corrected item-subscale correlation of less than 
0.40 or more than 0.8[37] .   The Cronbach alphas achieved by the subscales ranged 
from 0.70 to 0.85 (Table 2), thus satisfying the criterion proposed by Nunnally[35] of 0.7 
for comparing groups of patients.   
 
Validity 
The GSRQ demonstrated construct validity as shown by the statistically significant but 
modest correlations between the four GSRQ subscales with all the SF36 subscales and 
the EQ-5D index value (Table 3). 
 
Results of independent t-tests which compared patients’ subscale scores on the GSRQ 
showed that patients referred to receive an OGD scored worse on those subscales 
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related to upper GI symptoms and those patients referred to receive flexisigmoidoscopy 
scored worse on subscales related to lower GI symptoms (Table 4).  
 
Reproducibility 
Of the 1427 patients who returned both the baseline and the one month retest 
questionnaire, 956 (67%) did not report changes in their gastrointestinal symptoms, 371 
(26%) reported improvement, 82 (6%) reported deterioration, and 18 (1%) did not give 
any information about the status of their symptoms. The 956 stable patients reported 
significantly better GSRQ scores at one month by paired t-test but the differences were 
small (-0.06 to -4.95).   However, intraclass correlations between test and retest scores 
were good (0.71 to 0.77) (see Table 5).  
 
Responsiveness 
We assessed responsiveness for the 371 patients who reported an improvement and 
the 82 who reported deterioration in their gastrointestinal symptoms at one month.  
Those reporting an improvement had significantly better scores on all the four GSRQ 
subscales at one month by paired t-tests.  Responsiveness ratios for those reporting 
improvements were reasonable for all the four GSRQ subscales.  Those reporting a 
deterioration had worse GSRQ scores and the differences were significant for two of the 
subscales. Responsiveness ratio for those reporting deterioration were reasonable for 
two GSRQ subscales (see Table 6).  
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Discussion 
The GSRQ was developed and validated in patients with luminal gastrointestinal 
disorders and the results illustrate that the GSRQ is a valid questionnaire for assessing 
symptoms in patients with different GI disorders.  We were able to successfully use the 
questionnaire in patients where no confirmed diagnosis had been given and for patients 
with a confirmed disorder during the course of their disease.   
We were able to develop four interpretable factors in the GSRQ relevant to upper GI, 
lower GI, wind-related, and defecation-related symptoms. The GSRQ had good internal 
consistency as demonstrated by item-total correlations and Cronbach alphas within the 
appropriate ranges[35,37].  Good construct validity was demonstrated by significant but 
modest correlations between the GSRQ sub-scales and the generic SF-36 sub-scales the 
and EQ5D index value.  These data thereby validate that the GSRQ domains are 
measuring a set of gastrointestinal specific symptoms that impact on patients’ overall 
quality of life.    Variation in the GSRQ sub-domain scores is not associated with changes 
on generic health related quality of life instruments as different constructs are 
measured.  Good construct validity was also demonstrated by the ability of the GSRQ to 
distinguish between patients with different GI conditions.   Good test-retest reliability 
intra-class correlations and responsiveness ratios were shown for those patients 
reporting a change as illustrated the reproducibility and responsiveness of the GSRQ.  
We only used a limited patient assessment regarding whether their condition had 
changed.  A clinical assessment of change or more extensive assessment such as the 
Patient Global Impression of improvement may be more appropriate. 
22 
 
The GSRQ questionnaire was systematically developed and piloted.  Patients from 24 
hospitals across the United Kingdom (one pilot and 23 main study) with a variety of 
luminal GI symptoms were involved in testing the questionnaire as part of a randomised 
controlled trial.  The analysis was also thoroughly reviewed by patients, members of the 
public, psychometricians, statisticians and outcome specialists with experience in 
gastroenterology.  The meticulous development and validation enhanced the 
robustness of GSRQ. 
 
Given the high proportion of patients who present with luminal GI symptoms and the 
absence of or inappropriateness of many available tools for GI disorders, a valid and 
reliable system-specific scale like the GSRQ will help to monitor the long term care and 
disease course of the substantial amount of patients who attend GI departments with 
luminal gastrointestinal symptoms but have no confirmed diagnosis.  The GSRQ could 
also provide a patient-friendly template to guide the routine electronic collection of 
clinical information.  This would have the potential to enhance patient care at both 
individual and collective level.  
 
We were not able to assess whether differences exist between those patients with or 
without a diagnosis.  Further work is needed to determine what (if any) differences exist 
between these groups.  In addition, further work is needed to determine whether the 
GSRQ can be applied to other English speaking nations and translated into non-English 
versions.   
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Table 1.  Selection of questions for the GSRQ and its subscales 
 
Question No. 
(no of 
patients) 
Content (Symptom) Maximum 
response 
frequency 
(%) 
Order of 
question 
removal 
Significant factor coefficients (after 
rotation) 
F1 F2 F3 F4 
1 (1756) Heartburn 51  0.45 (0.48)   
2 (1752) Upper abdomen 
discomfort 
44  (0.47) 0.58   
3* (1131) Impact of symptom 1 or 2  49 1 Na na na na 
4 (1748) Reflux 59  0.62    
5 (1755) Nausea 58  0.73    
6  (1758) Retching 79  0.76    
7 (1761) Vomited 87  0.66    
8 (368) Blood in vomit if vomited 91 1 Na na na na 
9*(1519) Impact of symptom 4 to 7 70 1 Na na na na 
10 (1749) Belch 39   0.74   
11 (1761) Wind from bowel 28   0.58   
12 (1757) Trapped wind 30   0.72   
13 (1759) Gurgling in stomach 36   0.60   
14*(1748) Impact of symptom 10 to 
13 
66 1 Na na na na 
15 (1754) Food sticks in gullet 70  0.50    
16 (1750) Eating restricted 56  0.54 (0.45)   
17 (1767) Lack of appetite 64  0.62    
18* (1750) Impact of symptom 15 to 
17 
73 1 Na na na na 
19 (1722) Change in weight 56 2 Na na na na 
20 (1754) Frequent bowel 
movement 
47    0.84  
21 (1753) Loose stools 43    0.85  
22 (1744) Hard stools 58     0.82 
23 (1751) Constipation 62     0.86 
24 (1753) Urgent need to empty 
bowel 
55    0.79  
25 (1757) Incomplete bowel 
emptying 
42    (0.42) 0.59 
26 (1759) Bleeding in back passage 59 2 Na na na na 
27*(1764) Impact of symptom 20 to 
26 
65 1 Na na na na 
28 (1725) Change in symptoms 72 3 Na na na na 
29 (1757) Difficulty getting to sleep 58 4 Na na na na 
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30 (1752) Wake up 55 4 Na na na na 
Eigen value 5.62 2.37 1.96 1.38 
* Questions which patients skip if they did not have the relevant symptoms. 
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Table 2.  Internal consistency of the GSRQ subscales 
 
Sub-scale Minimum corrected 
item-subscale 
correlation 
Maximum corrected 
item-subscale 
correlation 
Cronbach’s 
alpha 
Upper GI 0.48 0.65 0.82 
Wind-related  0.47 0.70 0.78 
Lower GI 0.68 0.75 0.85 
Defecation-related  0.40 0.65 0.70 
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Table 3.  Correlation between the GSRQ subscales and the eight SF-36 subscales 
and EQ5D index value 
 
GSRQ subscales Upper GI Wind related 
symptoms 
Lower GI Defecation 
related symptoms 
SF-36 subscales and EQ5D 
index value 
I Functional status 
Physical Functioning -0.28 -0.20 -0.14 -0.19 
Social Functioning -0.41 -0.33 -0.24 -0.26 
Role limitations attributed 
to physical problems 
-0.32 -0.26 -0.22 -0.24 
Role limitations attributed 
to emotional problems 
-0.32 -0.26 -0.22 -0.26 
II Well-being 
Mental health -0.36 -0.31 -0.22 -0.25 
Vitality -0.40 -0.37 -0.24 -0.29 
Bodily pain -0.45 -0.41 -0.22 -0.27 
III Overall evaluation of health 
General health perception -0.38 -0.33 -0.23 -0.25 
     
EQ-5D index value -0.40 -0.33 -0.20 -0.23 
All correlations are significant at <0.001 level 
32 
 
 
Table 4.  Scores for the GSRQ subscales in patients referred for different procedure 
types at recruitment 
 
GSRQ subscales Mean scores for 
patients referred to 
receive OGD 
Mean scores for patients 
referred to receive 
flexisigmoidoscopy  
95% CI for difference 
Upper GI 25.64 13.06 (10.78, 14.37) 
Wind-related 47.19 37.91 (6.80, 11.75) 
Lower GI 22.88 33.87 (-13.77, -8.22) 
Defecation-
related 
18.86 24.96 (-8.26, -3.94) 
All differences significant at p < 0.001 level 
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Table 5.  Reproducibility of the GSRQ subscales for stable patients 
 
Scale 
 
Mean 
difference 
(retest-test) 
SD of the 
difference 
95% CI of the 
difference 
Intraclass 
correlation 
Upper GI -2.80 11.51 -3.54, -2.05 0.77 
Wind-related  -4.95 17.59 -6.09, -3.81 0.75 
Lower GI -2.82 20.11 -4.12, -1.52 0.75 
Defecation- 
related  
-0.06 16.65 -1.14, 1.02 0.71 
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Table 6.  Responsiveness of the GSRQ subscales for patients who improved or 
deteriorated 
 
Scales Average difference for 
subjects reporting a 
change (retest-test) 
Two-tailed 
significance 
SD of stable 
subjects 
Responsivness 
ratio 
Patients who improved 
Upper GI -6.60 <0.001 11.51 0.57 
Wind-related -12.58 <0.001 17.59 0.72 
Lower GI -8.06 <0.001 20.11 0.40 
Defecation-related -4.82 <0.001 16.65 0.29 
Patients who deteriorated 
Upper GI 3.92 0.005 11.51 0.34 
Wind-related 1.94 0.298 17.59 0.11 
Lower GI 0.15 0.956 20.11 0.008 
Defecation-related 6.48 0.009 16.65 0.39 
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Supplementary information (Web only material) 
Appendix 1: The initial version of the Gastrointestinal Symptom Rating 
Questionnaire (GSRQ) containing 30 items 
 
 
Appendix 2:  The Gastrointestinal Symptom Rating Questionnaire (GSRQ) developed 
following psychometric analysis (4 sub-scales; 19 items) 
 
 
 
